We are live on ! Find out more
TOVX icon

Theriva Biologics
TOVX

56 hedge funds and large institutions have $75.5M invested in Theriva Biologics in 2016 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 16 increasing their positions, 5 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

220% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 5

83% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 6

10% more funds holding

Funds holding: 51 → 56 (+5)

6% more capital invested

Capital invested by funds: $71.6M → $75.5M (+$3.98M)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0% more ownership

Funds ownership: 0% → 0% (+0%)

Holders
56
Holders Change
+5
Holders Change %
+9.8%
% of All Funds
1.49%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
11
Increased
16
Reduced
5
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BCM
Bridgeway Capital Management
Texas
+$601K
2
William Blair & Company
William Blair & Company
Illinois
+$481K
3
UBS Group
UBS Group
Switzerland
+$391K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$316K
5
CS
Credit Suisse
Switzerland
+$225K

Top Sellers

Rank Fund Capital Flow
1
BGA
Belmont Global Advisors
Texas
-$801K
2
VKH
Virtu KCG Holdings
New York
-$362K
3
IA
IFP Advisors
Florida
-$298K
4
Deutsche Bank
Deutsche Bank
Germany
-$150K
5
BCM
Bluefin Capital Management
New York
-$105K
Name Holding Trade Value Shares
Change 		Change in
Stake
Cambridge Investment Research Advisors
26
Cambridge Investment Research Advisors
Iowa
$179K – – –
Nomura Holdings
27
Nomura Holdings
Japan
$179K +$135K +9 New
SBIA
28
Sheaff Brock Investment Advisors
Indiana
$167K -$30.1K -2 -20%
State Street
29
State Street
Massachusetts
$127K – – –
Deutsche Bank
30
Deutsche Bank
Germany
$110K -$150K -10 -67%
HighTower Advisors
31
HighTower Advisors
Illinois
$104K – – –
Verition Fund Management
32
Verition Fund Management
Connecticut
$94K +$75.2K +5 New
Creative Planning
33
Creative Planning
Kansas
$92K – – –
M&T Bank
34
M&T Bank
New York
$86K – – –
AGM
35
Alpine Global Management
New York
$78K +$60.1K +4 New
SG Americas Securities
36
SG Americas Securities
New York
$69K +$45.1K +3 New
Stifel Financial
37
Stifel Financial
Missouri
$61K – – –
HLA
38
Hamilton Lane Advisors
Pennsylvania
$56K – – –
JG
39
Jefferies Group
New York
$56K +$45.1K +3 New
MWM
40
Mission Wealth Management
California
$55K – – –
WS
41
Wedbush Securities
California
$52K – – –
Royal Bank of Canada
42
Royal Bank of Canada
Ontario, Canada
$47K – – –
GC
43
Guggenheim Capital
Illinois
$34K +$15K +1 +100%
BCM
44
Bluefin Capital Management
New York
$32K -$105K -7 -78%
BA
45
BlackRock Advisors
Delaware
$32K – – –
Citadel Advisors
46
Citadel Advisors
Florida
$32K +$30.1K +2 New
TC
47
TradeLink Capital
Illinois
$29.3K +$15K +1 New
Fisher Asset Management
48
Fisher Asset Management
Washington
$29K – – –
BIM
49
BlackRock Investment Management
Delaware
$25K – – –
TSS
50
Two Sigma Securities
New York
$25K +$15K +1 New
1
2
3

TOVX Hedge Fund Activity: Q1 2016 in Review

56 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Theriva Biologics (TOVX) for Q1 2016, worth a combined $75.5M — up 5.6% from $71.6M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new TOVX positions and 6 closed out — a net gain of 5 holders — while 16 added to existing stakes and 5 trimmed.

The largest buyer was Bridgeway Capital Management, adding an estimated $601K. The largest seller was Belmont Global Advisors, exiting entirely with an estimated $801K sold.

  • 56 institutional investors held Theriva Biologics (TOVX) as of Q1 2016, up from 51 in Q4 2015.
  • Funds reported $75.5M of Theriva Biologics stock for Q1 2016, up 5.6% quarter-over-quarter.
  • 11 funds opened new Theriva Biologics positions in Q1 2016 and 6 closed out, a net change of +5 holders.
  • The largest Theriva Biologics buyer in Q1 2016 was Bridgeway Capital Management, an estimated $601K added.
  • The largest Theriva Biologics seller in Q1 2016 was Belmont Global Advisors, an estimated $801K sold.

Based on aggregated 13F filings for Q1 2016.